Sugi Predict

Sugi Predict / Compounds / SCHEMBL191087

SCHEMBL191087

SCHEMBL191087

C=C(C(=O)OC)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.48
▸ CES2 O00748 3/20 0.46
▸ CES1 P23141 3/20 0.46
▸ ALOX15 P16050 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ CA1 P00915 2/20 0.43
▸ CA2 P00918 2/20 0.43
▸ PTGS2 P35354 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ NLRP1 Q9C000 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22407012 0.91 HPGD (0.50) HPGDTSHRALDH1A1MAPTLMNA
SCHEMBL5057415 0.89 ALDH1A1 (0.46) CES2CES1TSHRALDH1A1MAPT
SCHEMBL9299063 0.82 MAPT (0.48) HPGDALDH1A1MAPTLMNAL3MBTL1
SCHEMBL4910303 0.82 CA1 (0.57) TSHRALDH1A1MAPTKDM4EL3MBTL1
SCHEMBL9300725 0.82 TDP1 (0.57) HPGDCES2CES1ALDH1A1MAPT
Butane SCHEMBL7720074 0.82 TDP1 (0.41) HPGDALDH1A1MAPTKDM4ECA1
SCHEMBL27468651 0.82 CA1 (0.57) HPGDTSHRALDH1A1MAPTLMNA
SCHEMBL27636035 0.81 CYP2C9 (0.44) HPGDALDH1A1MAPTLMNAKDM4E
SCHEMBL25107659 0.80 TPMT (0.45) HPGDALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL20013249 0.80 LMNA (0.44) HPGDTSHRALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250152588-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2025-05-15 — — US disclosed
CN-117677614-A Heterocyclic compound with AKT kinase inhibition activity, preparation method and medical application thereof 中国医药研究开发中心有限公司 2024-03-08 — — CN disclosed
CN-115160572-B Ultraviolet-curable SiC ceramic precursor, preparation method and ceramic coating repair method 航天材料及工艺研究所 2024-02-09 — — CN disclosed
WO-2023109540-A1 HETEROCYCLIC COMPOUND WITH AKT KINASE INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2023-06-22 — — WO disclosed
WO-2023109540-A1 HETEROCYCLIC COMPOUND WITH AKT KINASE INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2023-06-22 — — WO disclosed
US-20220226326-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2022-07-21 — — US disclosed
CN-112915092-A Combinations of AKT inhibitor compounds and abiraterone and methods of use 基因泰克公司 2021-06-08 — — CN disclosed
US-20200345735-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2020-11-05 — — US disclosed
CN-111643504-A Combinations of AKT inhibitor compounds and chemotherapeutic agents and methods of use 基因泰克公司 2020-09-11 — — CN disclosed
CN-110433165-A The combination and its application method of AKT and mek inhibitor compound GENENTECH INC 2019-11-12 — — CN disclosed
WO-2008006039-A1 DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2008-01-10 — — WO disclosed
WO-2008006025-A1 DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2008-01-10 — — WO disclosed
CN-1956949-A Substituted sulfonamides MERCK & CO INC (US) 2007-05-02 — — CN disclosed
CN-1871208-A Arylalkyl amines as cannabinoid receptor modulators MERCK & CO INC (US) 2006-11-29 — — CN disclosed
EP-0402312-B1 P-substituted propane-phosphinic acid compounds CIBA GEIGY AG (CH) 1995-01-25 — — EP disclosed
US-5190934-A Treatment of cognitive and memory disorders CIBA-GEIGY CORPORATION (US) 1993-03-02 — — US disclosed
US-5063225-A Antiarrhythmia ROUSSEL UCLAF (FR) 1991-11-05 — — US disclosed
EP-0402312-A2 P-substituted propane-phosphinic acid compounds CIBA-GEIGY AG (CH) 1990-12-12 — — EP disclosed
EP-0044835-A1 CATALYSED ALTERNATING COPOLYMERISATION AND PRODUCT NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1982-02-03 — — EP disclosed
WO-1981001289-A1 CATALYSED ALTERNATING COPOLYMERISATION AND PRODUCT BAMFORD C 1981-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220226326-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT1S1 HPGD 1065/4885CES2 3082/4885CES1 1397/4885
US-20250152588-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT1S1 HPGD 1065/4885CES2 3082/4885CES1 1397/4885
US-20200345735-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT1S1 HPGD 1065/4885CES2 3082/4885CES1 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.